2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.124 (Poster) Impact of Comprehensive vs. Limited NGS on Time to Result and Time to Treatment in Advanced NSCLC

PP01.124 (Poster) Impact of Comprehensive vs. Limited NGS on Time to Result and Time to Treatment in Advanced NSCLC

Pdf Summary

The study examined the impact of comprehensive versus limited next-generation sequencing (NGS) testing on the time it takes to obtain an actionable result and initiate treatment in patients with stage IV non-small cell lung cancer (NSCLC). The researchers analyzed data from 864 patients diagnosed with lung cancer between 2019 and 2020 at Northwestern Memorial Hospital and its clinical affiliates. Of these patients, 191 had stage IV NSCLC and underwent biopsy at one of the hospitals.<br /><br />The study found that most patients underwent NGS testing, with one-third of patients receiving comprehensive NGS panels. Comprehensive testing involved a full panel of over 500 genes and fusions, while limited testing required specific oncogene testing ordered by an oncologist. The researchers observed that comprehensive testing was associated with significantly longer times to obtain actionable results compared to non-comprehensive testing. However, there was no significant difference in the time it took for patients to initiate treatment between the two testing groups.<br /><br />The findings suggest that in settings where reflexive, internal molecular testing is not available, comprehensive molecular profiling should be utilized in advanced NSCLC cases. Reflex testing, which is not available in many practice settings, involves automatically ordering NGS testing at the time of NSCLC diagnosis. The study highlights the importance of comprehensive NGS testing in providing the necessary genetic information for treatment decision-making in advanced NSCLC patients.<br /><br />Overall, the study demonstrates that while comprehensive NGS testing may lead to longer times to obtain actionable results, it does not significantly delay the initiation of treatment. These results support the use of comprehensive molecular profiling in advanced NSCLC cases when reflexive testing is not available.

Asset Subtitle

Danielle Dressler

Keywords

next-generation sequencing

NGS testing

actionable result

treatment initiation

non-small cell lung cancer

NSCLC

comprehensive testing

limited testing

oncogene testing

molecular profiling